recombinant human rh cxcl11 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant human rh cxcl11
Recombinant Human Rh Cxcl11, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+cxcl11/Recombinant+Human+CXCL11%2FI-TAC+Protein%2C+CF/pm40341878-423-14-17
Average 94 stars, based on 7 article reviews
Recombinant Human Rh Cxcl11, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+cxcl11/Recombinant+Human+CXCL11%2FI-TAC+Protein%2C+CF/pm40341878-423-14-17
Average 94 stars, based on 7 article reviews
recombinant human rh cxcl11 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Recombinant:Article Title: Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Article Snippet: Interactions between chemokines and enzymes are vital in immunoregulation.. Structural protein citrullination by peptidylarginine deiminase (PAD) has been associated with autoimmunity.. In this report, we identified a novel naturally occurring posttranslational modification of chemokines, that is, the deimination of arginine at position 5 into citrulline of CXC chemokine ligand 10 (CXCL10) by rabbit PAD and human PAD2. Article Title: Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders Article Snippet: The cocktail was a mix of recombinant human CCL2/MCP1 (Mucin stalk Chimera) carrier free (R&D Systems, Minneapolis, Minn., US; cat nr: 979-MC/CF), recombinant human CCL3/MIP1 alpha carrier free (R&D Systems; cat nr: 270-LD/CF), recombinant human CCL5/RANTES (Mucin stalk Chimera) carrier free (R&D Systems; cat nr: 978-RN/CF), recombinant human CXCL11/I-TAC carrier free (R&D Systems; cat nr: 672-IT/CF), and recombinant human CXCL12/SDF1alpha carrier free (R&D Systems; cat nr: 350-NS/CF;)). .. The cocktail was a mix of recombinant human CCL2/MCP1 (Mucin stalk Chimera) carrier free (R&D Systems, Minneapolis, Minn., US; cat nr: 979-MC/CF), recombinant human CCL3/MIP1 alpha carrier free (R&D Systems; cat nr: 270-LD/CF), recombinant human CCL5/RANTES (Mucin stalk Chimera) carrier free (R&D Systems; cat nr: 978-RN/CF), Article Title: Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Article Snippet: Adoptive immunotherapy of cancer patients with cytolytic T lymphocytes (CTL) has been hampered by the inability of the CTL to home into tumors in vivo.. Chemokines can attract T lymphocytes to the tumor site, as demonstrated in animal models, but the role of chemokines in T-lymphocyte trafficking toward human tumor cells is relatively unexplored.. In the present study, the role of chemokines and their receptors in the migration of a colon carcinoma (CC) patient’s CTL toward autologous tumor cells has been studied in a novel three-dimensional organotypic CC culture. Article Title: SDF-1α induces differential trafficking of CXCR4-CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. Article Snippet: Platelet-derived SDF-1 (CXCL12) mediates inflammatory and regenerative mechanisms.. The present study characterizes the effect of SDF-1 ligation in platelets.. SDF-1 (0–100 M) dose and time dependently caused internalization of its receptor CXCR4 (28.9 1.6 vs. 16.1 1.9 in SDF-1 -treated platelets), coupled to the surface externalization of CXCR7 (65.5 8 vs. 162.8 27.6 following SDF-1 treatment), both in vitro and in vivo. Article Title: Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture Article Snippet: Reagents The following monoclonal antibodies (mAbs) were used: HLA-class I-specific mAb W6/32 and HLA-class II-specific mAb B33.1 and D1.B6 (obtained from Dr B. Perussia, Thomas Jefferson University, and Dr G. Trinchieri, The Wistar Institute); mAb Nok-1 to Fas ligand (PharMingen, Los Angeles, CA, USA); mAb CH-11 to CD95 and anti-CD11a mAb (Immunotech, Westbrook, ME, USA); fluoresceinated or phycoerythrin-labeled anti-CD:4, 8, 25, 29, 40, 40L, 44, 49a, 49b, 80, and 54 (PharMingen, Los Angeles, CA, USA); anti-CXCL-11 mAb; anti-human CCR:1, 2, 3, 5, 6, 7, 9, and CXCR:1, 2, 3, 4, 5, and 6 mAbs (R&D Systems, Minneapolis, MN, USA); anti-human CCR:4, 8, and 10 mAbs (Imgenex, San Diego, CA, USA); anti-CCR11 and -CX3CR1 polyclonal Abs (Abcam, Cambridge, MA, USA); fluoresceinated goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA). .. Article Title: Macrophage Migration Inhibitory Factor Limits Activation-Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling Article Snippet: .. These findings link the proinflammatory role of MIF with an antithrombotic effect and suggest targeting the MIF-CXCR7 interaction may be a potential strategy to control inflammation. at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from 1 Supplemental Material Materials: Recombinant murine/human/feline SDF-1α/CXCL12, Article Title: In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2 Article Snippet: The following monoclonal antibodies (mAb) were used: mAb Nok-1 to Fas ligand (BD-PharMingen, San Diego, CA); mAb CH-11 to CD95 and anti-CD11a mAb (Immunotech, Westbrook, ME); fluoresceinated (FITC) or phycoerythrin (PE) -conjugated anti-CD:4, 8, 25, 29, 40, 40L, 44, 49a, 49b, 54 and 80; anti-CXCL-11 mAb; anti-human CCR:1, 2, 3, 5, 6, 7 and 9 mAb; anti- CXCR:1, 2, 3, 4, 5 and 6 mAb (R&D Systems, Minneapolis, MN); anti-human CCR:4, 8, and 10 mAb (Imgenex, San Diego, CA); anti-CCR11 and -CX3CR1 polyclonal Ab (Abcam, Cambridge, MA); FITC conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA). .. Article Title: Tumor Cell-Intrinsic Circular RNA CircFNDC3B Attenuates CD8+ T Cells Infiltration in Non-Small Cell Lung Cancer Article Snippet: .. When indicated, anti-CXCL11 (R&D Systems, MAB672, 1μg/ml), anti-CXCL10 (R&D Systems, MAB266, 1μg/ml), Control:Article Title: Macrophage Migration Inhibitory Factor Limits Activation-Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling Article Snippet: .. These findings link the proinflammatory role of MIF with an antithrombotic effect and suggest targeting the MIF-CXCR7 interaction may be a potential strategy to control inflammation. at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from at New York University/ Medical Center--New York on October 15, 2014http://circres.ahajournals.org/Downloaded from 1 Supplemental Material Materials: Recombinant murine/human/feline SDF-1α/CXCL12, |
